Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
BMC Cancer|April 3, 2012
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cellsMartin Laschak, Klaus-Dieter Spindler, Andres J Schrader, et al.
Cancer|August 27, 2004
Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinomaAxel Heidenreich, Frank Sommer, Carsten H Ohlmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate CancerChristof Bernemann, Verena Humberg, Barbara Thielen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2016
Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate CancerKambiz Rahbar, Matthias Weckesser, Sebastian Huss, et al.
BMC Urology|December 14, 2011
Caveolin 1 protein expression in renal cell carcinoma predicts survivalSandra Steffens, Andres J Schrader, Hanna Blasig, et al.
World Journal of Urology|February 11, 2012
The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcomeFlorian Jentzmik, Andres J Schrader, Robert de Petriconi, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 2, 2015
The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cellsKonrad Steinestel, Stefan Eder, Konstantin Ehinger, et al.
World Journal of Surgical Oncology|October 14, 2011
Partial nephrectomy using porcine small intestinal submucosaThomas J Schnoeller, Robert de Petriconi, Robert Hefty, et al.
Anti-Cancer Drugs|April 23, 2005
Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinomaAndres J Schrader, Axel Heidenreich, Axel Hegele, et al.
World Journal of Urology|February 25, 2012
AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cellsWolfgang Streicher, Friedemann Zengerling, Martin Laschak, et al.
Pageof 7